<DOC>
	<DOCNO>NCT01895491</DOCNO>
	<brief_summary>The main objective study evaluate safety VM206RY subject expression HER2 breast cancer .</brief_summary>
	<brief_title>Safety Study VM206RY Subjects With Expression HER2 Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women , 20 year age Stage 3 4 breast cancer Unresectable breast cancer Expression Her2 one follow criterion include Prior use Her2targeted therapy ( Herceptin , Tykerb , taxane capecitabine ) responding , Immunohistochemistry ( IHC ) 3+ , IHC 2+ FISH+ , SISH+ Patients receive treatment three time continuously Different chemotherapy respond , Immunohistochemistry ( IHC ) 2+ FISH SISH , Immunohistochemistry ( IHC ) 1+ Prior use six chemotherapy ( Anthracycline , Taxane , Gemcitabine , Capecitabine , Vinorelbine , Cyclophosphamide ) responding , Immunohistochemistry ( IHC ) 2+ FISH SISH , Immunohistochemistry ( IHC ) 1+ One measurable ( assessable ) lesion breast metastatic site Spiral CT : ≥ 10mm diameter general measurement method ( CT , Xray , MRI ) : ≥ 20mm diameter Life expectancy 6 month Signed informed consent Prior use breast cancer vaccine Active history cardiovascular disease within past 3 month : Active uncontrolled cardiac disease , include cardiomyopathy , CHF ( NYHA Class III~IV ) , unstable angina , family history congenital long QT syndrome QT/QTc interval &gt; 0.45 sec torsade de point ( TdP ) , history idiopathic ventricular tachycardia ventricular fibrillation , LVEF &lt; 50 % Patients coronary artery disease ( myocardial infarction , angina , etc . ) history coronary artery disease Patients require hospitalization severe fever require antibiotic treatment serious infection Patients confirm CNS metastasis . ( Only , patient stable brain metastasis permit . Among patient symptom , see progression register last 2 month ) History prior malignancy breast cancer within past 5 year Patients exist condition history autoimmune disease immunodeficiency disease ECOG score ≥ 3 Patients severe dysfunction major organ Blood : WBC &lt; 3,000/㎕ ; Platelet &lt; 100,000/㎕ ; Hematocrit &lt; 30 Liver : Total bilirubin ≥ 1.5 x ULN ; ALT/AST ≥ 2.5 x ULN Kidney : Creatinine ≥ 1.5 x ULN Abnormal value antinuclear Ab , antidoublestranded DNA C3 , judge investigator History surgical procedure , chemotherapy , Herceptin treatment , corticosteroid therapy , immunosuppressant therapy radiotherapy within past 4 week HIV Ag/Ab , HBs Ag , HCV Ab HTLV1 Ab positive Psychotropic drug misuse/abuse alcoholism Prior use vaccine within past 4 week Cumulative dose prior doxorubicin &gt; 360 ㎎/㎡ epirubicin &gt; 720 ㎎/㎡ Women pregnant breastfeed n't agree use contraceptive study period . Patients participate clinical trial enrol clinical trial within 4 week . ( Only patient , take survey DNA test without drugtreatment , permit . ) Patients ineligible participate study , judge investigator . Patients prohibit administer GMCSF prior use GMCSF within past 4 week . Patients expect hypersensitivity investigational product ( VM206RY ) component product . Due malignancy neoplasm , patient require supplementary oxygen severe dyspnea rest Patients hypertension [ inadequately control hypertension ( systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ) ] history hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>